Physician profile

Michael S Maher

Cardiovascular Disease · Scottsdale, AZ

NPI 1235122755

$1,365.39

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $707.67 2019-2022
Boston Scientific Corporation $91.95 2019-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $75.37 2019-2021
Pfizer INC. $71.91 2019-2022
Janssen Pharmaceuticals, INC $70.96 2021-2022
Medtronic Vascular, INC. $53.41 2019-2020
Merck Sharp & Dohme LLC $40.59 2022
Sanofi-Aventis U.S. LLC $35.61 2019-2020
E.R. Squibb & Sons, L.L.C. $33.78 2019-2021
Edwards Lifesciences Corporation $28.06 2021
Amgen INC. $27.88 2019-2022
Abbott Laboratories $24.12 2019
Biosense Webster, INC. $20.15 2020
Chiesi USA, INC. $18.79 2020
Alnylam Pharmaceuticals INC. $15.32 2020
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $13.83 2021
Boehringer Ingelheim Pharmaceuticals, INC. $13.22 2019
Astrazeneca Pharmaceuticals Lp $11.93 2021
Itamar Medical INC $10.84 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael S Maher

$1,365.39

in general payments reported 2019-2025

Years
2019-2022
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/55096/michael-s-maher

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.